Moreover, it has been described that FGF21 inhibits ApoA expression in human hepatoma cell line HepG2 via the FGF21-ERK1/2-Elk-1 pathway indicating the involvement of this molecule in the metabolic pathway of lipoproteins [25]. This evidence concerns the gene FGF21 and hepatocellular carcinoma.